At Ascentage Pharma, we are dedicated to developing innovative therapies that can change the lives of patients with cancer, hepatitis B and age-related diseases. We have built a robust pipeline of eight clinical drug candidates, and are conducting over 30 clinical trials in China, the United States, Australia and Europe. Our apoptosis-targeted drug candidates are intended to treat cancer and other diseases by restoring the normal function of key apoptotic pathways. We are also developing several next generation tyrosine kinase inhibitors (TKIs) to treat diseases with high unmet medical needs. We are developing these compounds for use as a single agent or in combination with other therapies.
Ascentage Pharma is committed to develop investigational new drugs that transform the lives of patients suffering from cancers, chronic hepatitis B, and age-related diseases. These include potential innovative therapies to manage diseases/conditions that are otherwise difficult to treat. Central to Ascentage Pharma’s vision of enhancing patients’ lives is our pledge to bring these novel targeted therapies to patients as rapidly as possible.
While fulfilling this pivotal aim, we are also mindful of patient safety and the imperative to abide by proven safeguards to protect health and well-being. As we develop innovative therapies to treat a range of diseases/conditions, we are making our investigational drugs available to patients via participation in one of our many clinical trials under the supervision of health care authorities and Institutional Review Board.
Once clinical evidence supporting the safety and efficacy of our therapies has met the formal scientific evaluations, we will start considering requests for our investigational drugs outside of clinical trials through our expanded-access program. Our expanded-access program will include independent review by the US Food and Drug Administration.
We will announce specific expanded-access programs involving our therapies well in advance of respective market launches and according to the following principles: